Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
An open-label, non-randomized, phase II study to assess the safety and efficacy of
Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in Borderline Resectable Esophageal
Squamous Cell Carcinoma patients
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
CSPC Pharmaceutical Group Limited Innovent Biologics (Suzhou) Co. Ltd.